Oscotec Inc.

Translating science into medicine
회원가입
PRESS
List of Articles
Date Site Media Pipeline
2021-03-02 Other news to note for March 2, 2021 BioWorld Oscotec
2023-09-14 Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease Biospace Oscotec
2024-02-23 Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease yahoo! finance Oscotec
2018-05-16 Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018 Businesswire Lazertinib
2018-06-03 "ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC" Businesswire Lazertinib
2018-11-05 Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech BusinessKorea Lazertinib
2019-11-04 Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study THE LANCET ONCOLOGY Lazertinib
2019-12-12 Yuhan to start phase-3 trial on lung cancer drug Lazertinib KBR (; Korea Biomedical Review) Lazertinib
2019-12-14 Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC Targeted Oncology Lazertinib
2020-05-18 Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations BioSpace Lazertinib
2018-03-14 More than half of Korean biopharma firms view R&D investments as assets. The Korea Herald Industry
2019-01-28 Genosco gears up for IPO THE INVESTOR Genosco
Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
서버에 요청 중입니다. 잠시만 기다려 주십시오...